Quarterly ResultJun 15, 2026, 04:52 PM
High Tide Reports Record Q2 Revenue of $179.3M, Adjusted EBITDA $13.9M
AI Summary
High Tide Inc. announced its second quarter 2026 financial results, featuring record revenue of $179.3 million, a 30% increase year-over-year, and record Adjusted EBITDA of $13.9 million, up 73% year-over-year. The company also reported positive free cash flow of $1.5 million and net income. Key drivers included strong performance from its German medical cannabis subsidiary, Remexian Pharma GmbH, which generated $31.6 million in revenue with 27% gross margins, and continued growth in its Canadian retail operations, evidenced by a 39% increase in Cabana Club memberships. High Tide also secured $40 million in credit facilities from Bank of Montreal to support growth.
Key Highlights
- High Tide Inc. reported record Q2 2026 revenue of $179.3 million, up 30% YoY.
- Adjusted EBITDA reached a record $13.9 million, up 73% YoY.
- The company generated $1.5 million in free cash flow in Q2 2026.
- German subsidiary Remexian Pharma GmbH achieved record revenue of $31.6 million with 27% gross margins.
- High Tide secured credit approval for $40 million in senior secured credit facilities from Bank of Montreal.
- Canadian Cabana Club membership exceeded 2.65 million, up 39% YoY.
- ELITE members in Canada surpassed 178,000, up 84% YoY.
- Income from operations was a record $6.1 million, up 554% YoY.
Price Impact
More from HITI